EGFR L747P
|
NSCLC
|
EGFR L747P
|
NSCLC
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR L747P
|
LUAD
|
EGFR L747P
|
LUAD
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR L747P
|
LUAD
|
EGFR L747P
|
LUAD
|
gefitinib Sensitive: C4 – Case Studies
|
gefitinib Sensitive: C4 – Case Studies
|
EGFR L747P
|
LUAD
|
EGFR L747P
|
LUAD
|
osimertinib Sensitive: C4 – Case Studies
|
osimertinib Sensitive: C4 – Case Studies
|
EGFR L747P
|
NSCLC
|
EGFR L747P
|
NSCLC
|
gefitinib Resistant: C4 – Case Studies
|
gefitinib Resistant: C4 – Case Studies
|
EGFR L747P
|
LUAD
|
EGFR L747P
|
LUAD
|
erlotinib Sensitive: C4 – Case Studies
|
erlotinib Sensitive: C4 – Case Studies
|